Vivani Medical, Inc. (VANI), on Wednesday, announced promising preclinical data for its semaglutide implant in development ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Recent research found that people taking semaglutide—the active ingredient in Ozempic and Wegovy—had more hair loss than ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

GLP-1 drugs have revolutionised the treatment of obesity, but the very reason they are effective is also why it's vital to ...

A new study has revealed that the ingredients of the popular weight loss drug Ozempic are linked to hair loss.According to ...

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

Make sure to tune in to KTIV’s half-hour live special, “Shifting the Scale”, airing Thursday night at 6:30 on KTIV. CNOS ...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced positive data for NPM-139, its subdermal semaglutide implant for ...

Researchers assessed data from 16 million patients from 2006 to 2020 taking semaglutide-based drugs; the active ingredient in Wegovy.

Vivani Medical (VANI) announced promising preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight ...